文献速递生殖医学

第二代IVF/ICSI治疗前子宫内膜搔刮的经济学评价:SCRaTCH随机对照试验的成本-效果分析

Economic evaluation of endometrial scratching before the second IVF/ICSI treatment: a cost-effectiveness analysis of a randomized controlled trial (SCRaTCH trial).
PubMed 文献 · Hum Reprod · 2022-01-01

基于荷兰多中心SCRaTCH随机对照试验,对首次完整IVF/ICSI周期失败后行第二代治疗前单次子宫内膜搔刮与不搔刮进行成本-效果分析,随访12个月。搔刮组12个月活产率44.1% vs 对照组39.3%(风险差4.8%,95%CI -1.6%至+11.2%),平均费用高283欧元(95%CI -299至810欧元),点估计ICER为每增加一例活产5846欧元。因临床效果不确定性高,结论需谨慎解读。

要点

  • 搔刮组12个月活产率44.1%,对照组39.3%,风险差4.8%(95%CI -1.6%至+11.2%),未达统计学显著。
  • 搔刮组平均费用高283欧元(95%CI -299至810欧元),点估计ICER为每增加一例活产5846欧元。
  • 成本-效果可接受曲线显示,若社会愿为每增加一例活产支付约17500欧元,搔刮具有成本-效果的概率为80%。

核心结论

  • 单次子宫内膜搔刮的增量成本-效果比(ICER)为每增加一例活产6524欧元,但由于活产率增加存在不确定性,须谨慎解读。
  • 点估计ICER为每增加一例活产5846欧元,ICER估计伴随高度不确定性。

研究设计与样本

  • 基于荷兰多中心随机对照试验(SCRaTCH试验)的经济学评价。
  • 纳入2016年1月至2018年7月933例首次IVF/ICSI周期失败女性,比较第二代治疗前单次搔刮与不搔刮。
  • 随机化后随访12个月,从医疗保健和社会视角计算直接医疗成本与生产力损失成本。

主要发现

  • 搔刮组12个月随访活产率为44.1%,对照组为39.3%,风险差4.8%(95%CI -1.6%至+11.2%)。
  • 搔刮组平均费用较对照组高283欧元(95%CI -299至810欧元)。
  • 点估计ICER为每增加一例活产5846欧元。
  • 成本-效果可接受曲线显示,若社会愿为每增加一例活产支付约17500欧元,搔刮具有成本-效果的概率为80%。

关键数值与推荐

  • 以随机化后12个月随访生化妊娠导致活产为主要结局,以第二代新鲜IVF/ICSI治疗(即随机化后第一次)后活产为次要结局。
  • 采用Bootstrap重抽样估计成本与效应差异及ICER的不确定性。
  • 敏感性分析与情景分析中引入单次搔刮的不同单位成本,包括适用于英国的单位成本。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 效应存在高度不确定性,主要是临床效应即活产机会的差异,导致目前无法得出单一明确的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is a single endometrial scratch prior to the second fresh IVF/ICSI treatment cost-effective compared to no scratch, when evaluated over a 12-month follow-up period? SUMMARY ANSWER: The incremental cost-effectiveness ratio (ICER) for an endometrial scratch was €6524 per additional live birth, but due to uncertainty regarding the increase in live birth rate this has to be interpreted with caution. WHAT IS KNOWN ALREADY: Endometrial scratching is thought to improve the chances of success in couples with previously failed embryo implantation in IVF/ICSI treatment. It has been widely implemented in daily practice, despite the lack of conclusive evidence of its effectiveness and without investigating whether scratching allows for a cost-effective method to reduce the number of IVF/ICSI cycles needed to achieve a live birth. STUDY DESIGN, SIZE, DURATION: This economic evaluation is based on a multicentre randomized controlled trial carried out in the Netherlands (SCRaTCH trial) that compared a single scratch prior to the second IVF/ICSI treatment with no scratch in couples with a failed full first IVF/ICSI cycle. Follow-up was 12 months after randomization.Economic evaluation was performed from a healthcare and societal perspective by taking both direct medical costs and lost productivity costs into account. It was performed for the primary outcome of biochemical pregnancy leading to live birth after 12 months of follow-up as well as the secondary outcome of live birth after the second fresh IVF/ICSI treatment (i.e. the first after randomization). To allow for worldwide interpretation of the data, cost level scenario analysis and sensitivity analysis was performed. PARTICIPANTS/MATERIALS, SETTING, METHODS: From January 2016 until July 2018, 933 women with a failed first IVF/ICSI cycle were included in the trial. Data on treatment and pregnancy were recorded up until 12 months after randomization, and the resulting live birth outcomes (even if after 12 months) were also recorded.Total costs were calculated for the second fresh IVF/ICSI treatment and for the full 12 month period for each participant. We included costs of all treatments, medication, complications and lost productivity costs. Cost-effectiveness analysis was carried out by calculating ICERs for scratch compared to control. Bootstrap resampling was used to estimate the uncertainty around cost and effect differences and ICERs. In the sensitivity and scenario analyses, various unit costs for a single scratch were introduced, amongst them, unit costs as they apply for the United Kingdom (UK). MAIN RESULTS AND THE ROLE OF CHANCE: More live births occurred in the scratch group, but this also came with increased costs over a 12-month period. The estimated chance of a live birth after 12 months of follow-up was 44.1% in the scratch group compared to 39.3% in the control group (risk difference 4.8%, 95% CI -1.6% to +11.2%). The mean costs were on average €283 (95% CI: -€299 to €810) higher in the scratch group so that the point average ICER was €5846 per additional live birth. The ICER estimate was surrounded with a high level of uncertainty, as indicated by the fact that the cost-effectiveness acceptability curve (CEAC) showed that there is an 80% chance that endometrial scratching is cost-effective if society is willing to pay ∼€17 500 for each additional live birth. LIMITATIONS, REASONS FOR CAUTION: There was a high uncertainty surrounding the effects, mainly in the clinical effect, i.e. the difference in the chance of live birth, which meant that a single straightforward conclusion could not be ascertained as for now. WIDER IMPLICATIONS OF THE FINDINGS: This is the first formal cost-effectiveness analysis of endometrial scratching in women undergoing IVF/ICSI treatment. The results presented in this manuscript cannot provide a clear-cut expenditure for one additional birth, but they do allow for estimating costs per additional live birth in different scenarios once the clinical effectiveness of scratching is known. As the SCRaTCH trial was the only trial with a follow-up of 12 months, it allows for the most complete estimation of costs to date. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by ZonMW, the Dutch organization for funding healthcare research. A.E.P.C., F.J.M.B., E.R.G. and C.B. L. reported having received fees or grants during, but outside of, this trial. TRIAL REGISTRATION NUMBER: Netherlands Trial Register (NL5193/NTR 5342).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. van Hoogenhuijze NE, van Eekelen R, Mol F, et al. Economic evaluation of endometrial scratching before the second IVF/ICSI treatment: a cost-effectiveness analysis of a randomized controlled trial (SCRaTCH trial). Hum Reprod. 2022. PMID: 34864993. doi:10.1093/humrep/deab261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。